logo-loader

Valeo Pharma sees 80% increase in revenue year over year as company reports Q2 financials

Published: 10:54 15 Jun 2022 EDT

Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has reported very good numbers in Q2 2022. Those numbers include revenues of $4.8 million, up 80% over Q2-21. Saviuk telling Proactive the company saw gross margins of $1.7 million, up 134% over Q2-21. Saviuk says the numbers are being led by their 3 lead brands, Redesca, Enerzair and Atectura. In fact, Redesca has captured a 54% share of the Canadian low molecular weight heparin biosimilar market.

Valeo Pharma Q1 numbers shows asthma product revenues increasing by 58%

Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to discuss the company's financial results for the first quarter ended January 31, 2024. Valeo Pharma reported revenues of $13.5 million in Q1-24, compared to $13.1 million in Q1-23 and $13.1 million in Q4-23, representing a 3%...

1 week, 3 days ago